One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.
James E. Signorovitch
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Eric Qiong Wu
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Keith A. Betts
Consultant or Advisory Role - Novartis
Research Funding - Novartis
William M. Reichmann
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Darren Thomason
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Philip J Galebach
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Lei Chen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis